FDA cites Lupin for lax oversight of equipment breakdowns, poor follow up and more

The US Food and Drug Administration (FDA) chastised India-based Lupin in a recent untitled letter for a multitude of good manufacturing practice (GMP) violations, including lax investigations into equipment failures and poor complaint follow-up.